Bio-Thera And Stada Joins Forces On Golimumab, With Up To $160m On The Table
Stada Looking To Scale Up In EU Immunology; Appreciates Bio-Thera’s US Approvals
With European biosimilar approvals already in hand for the immunology giants adalimumab and ustekinumab, Stada has allied with Bio-Thera Solutions to bring onboard the commercialization rights for the Chinese firm’s proposed golimumab biosimilar, which currently has a limited pool of chasers.
